X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (76435) 76435
Publication (5215) 5215
Newsletter (3037) 3037
Book Review (771) 771
Book Chapter (437) 437
Newspaper Article (279) 279
Dissertation (156) 156
Magazine Article (153) 153
Conference Proceeding (123) 123
Government Document (28) 28
Book / eBook (16) 16
Trade Publication Article (11) 11
Paper (9) 9
Data Set (5) 5
Web Resource (5) 5
Reference (4) 4
Journal / eJournal (2) 2
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (50495) 50495
male (23175) 23175
female (22768) 22768
animals (20014) 20014
index medicus (17813) 17813
middle aged (14913) 14913
aged (12159) 12159
adult (10936) 10936
tissue plasminogen activator (10043) 10043
plasminogen-activator (10001) 10001
peripheral vascular disease (8820) 8820
fibrinolysis (8112) 8112
stroke (7816) 7816
thrombolytic therapy (7479) 7479
tissue plasminogen activator - therapeutic use (7432) 7432
hematology (7413) 7413
mice (7118) 7118
biochemistry & molecular biology (6719) 6719
thrombolysis (6032) 6032
tissue-plasminogen activator (5891) 5891
treatment outcome (5754) 5754
fibrinolytic agents - therapeutic use (5739) 5739
clinical neurology (5720) 5720
time factors (5590) 5590
expression (5047) 5047
research (4897) 4897
rats (4700) 4700
risk factors (4684) 4684
plasminogen (4521) 4521
aged, 80 and over (4426) 4426
cells, cultured (4331) 4331
cardiac & cardiovascular systems (4319) 4319
urokinase (4081) 4081
oncology (4035) 4035
tissue plasminogen activator - administration & dosage (3974) 3974
plasminogen-activator inhibitor-1 (3960) 3960
stroke - drug therapy (3794) 3794
neurosciences (3670) 3670
urokinase-type plasminogen activator - metabolism (3666) 3666
cell biology (3660) 3660
therapy (3552) 3552
analysis (3458) 3458
surgery (3419) 3419
thrombosis (3406) 3406
acute ischemic-stroke (3331) 3331
plasminogen - metabolism (3330) 3330
myocardial infarction - drug therapy (3151) 3151
care and treatment (3146) 3146
fibrinolytic agents - administration & dosage (2975) 2975
thrombolytic therapy - methods (2969) 2969
prognosis (2956) 2956
plasminogen activator inhibitor 1 - metabolism (2901) 2901
ischemia (2805) 2805
plasminogen activator inhibitor 1 - genetics (2781) 2781
molecular sequence data (2774) 2774
tissue-plasminogen-activator (2774) 2774
urokinase-type plasminogen activator - therapeutic use (2739) 2739
tissue plasminogen activator - metabolism (2686) 2686
pharmacology & pharmacy (2630) 2630
medicine, general & internal (2626) 2626
retrospective studies (2593) 2593
kinetics (2556) 2556
proteins (2556) 2556
acute myocardial-infarction (2498) 2498
prospective studies (2478) 2478
plasminogen activator inhibitor 1 - blood (2477) 2477
health aspects (2412) 2412
amino acid sequence (2400) 2400
cancer (2379) 2379
fibrinolysis - drug effects (2367) 2367
adolescent (2353) 2353
endothelial-cells (2351) 2351
inflammation (2345) 2345
myocardial-infarction (2272) 2272
cell line (2265) 2265
cells (2260) 2260
disease models, animal (2258) 2258
mortality (2234) 2234
plasminogen activators - metabolism (2208) 2208
plasma (2147) 2147
article (2142) 2142
acute disease (2130) 2130
streptokinase (2107) 2107
dose-response relationship, drug (2105) 2105
fibrin (2104) 2104
medicine, research & experimental (2048) 2048
gene expression (2025) 2025
tissue plasminogen-activator (1970) 1970
brain ischemia - drug therapy (1964) 1964
physiological aspects (1951) 1951
disease (1943) 1943
metastasis (1941) 1941
plasminogen activator (1901) 1901
receptor (1897) 1897
trial (1877) 1877
receptors, urokinase plasminogen activator (1872) 1872
tissue plasminogen activator - adverse effects (1858) 1858
coagulation (1847) 1847
plasminogen activators (1831) 1831
endocrinology & metabolism (1826) 1826
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (74056) 74056
German (1364) 1364
Japanese (1267) 1267
French (774) 774
Chinese (747) 747
Russian (654) 654
Spanish (450) 450
Polish (293) 293
Italian (261) 261
Korean (104) 104
Czech (79) 79
Portuguese (62) 62
Turkish (45) 45
Danish (42) 42
Ukrainian (40) 40
Dutch (37) 37
Hungarian (34) 34
Swedish (25) 25
Norwegian (20) 20
Slovak (14) 14
Bulgarian (13) 13
Finnish (12) 12
Serbian (11) 11
Croatian (10) 10
Hebrew (9) 9
Persian (9) 9
Romanian (9) 9
Icelandic (3) 3
Catalan (2) 2
Bosnian (1) 1
Indonesian (1) 1
Slovenian (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Brain, ISSN 0006-8950, 2012, Volume 135, Issue 11, pp. 3251 - 3264
The neurovascular unit provides a dynamic interface between the circulation and central nervous system. Disruption of neurovascular integrity occurs in... 
traumatic brain injury | matrix metalloproteinase-3 | plasminogen activator inhibitor-1 | tissue plasminogen activator | neurovascular unit | MULTIPLE-SCLEROSIS LESIONS | RECEPTOR-RELATED PROTEIN | TPA | FOCAL CEREBRAL-ISCHEMIA | BARRIER BREAKDOWN | NEUROSCIENCES | CLINICAL NEUROLOGY | STROKE | MATRIX METALLOPROTEINASES | CENTRAL-NERVOUS-SYSTEM | EXPRESSION | BLOOD | Capillary Permeability - physiology | Tissue Plasminogen Activator - metabolism | Brain Injuries - drug therapy | Humans | Middle Aged | Injections, Intraventricular | Capillary Permeability - drug effects | Male | Brain Injuries - metabolism | Brain Injuries - physiopathology | Plasminogen Activator Inhibitor 1 - physiology | Matrix Metalloproteinase Inhibitors - therapeutic use | Brain - metabolism | Dose-Response Relationship, Drug | Brain - blood supply | Tissue Plasminogen Activator - antagonists & inhibitors | Plasminogen Activator Inhibitor 1 - metabolism | Aged, 80 and over | Recovery of Function - physiology | Adult | Disease Models, Animal | Albumins - metabolism | Mice, Inbred C57BL | Plasminogen Activator Inhibitor 1 - administration & dosage | Tissue Plasminogen Activator - administration & dosage | Tissue Plasminogen Activator - physiology | Animals | Brain Injuries - cerebrospinal fluid | Aged | Mice | Matrix Metalloproteinases - metabolism | Stroke | Central nervous system | Membrane permeability | Albumin | Homeostasis | Cerebrospinal fluid | Matrix metalloproteinase | Permeability | Trauma | Plasmin | t-Plasminogen activator | lipoprotein receptors | neuroserpin | plasminogen | Proteolysis | Plasma membranes | Chromium | Serine proteinase | Brain injury | Original
Journal Article
Biochemical Journal, ISSN 0264-6021, 12/2007, Volume 408, Issue 2, pp. 203 - 210
PAI-I and PAI-2 (plasminogen-activator inhibitor types I and 2) are inhibitors of cell surface upA (urokinase plasminogen activator). However, tumour... 
Serpin (serine protease inhibitor) | Plasminogen-activator inhibitor type 2 (PAI-2) | Urokinase plasminogen activator (uPA) | Very-low-density lipoprotein receptor (VLDLr) | Plasminogen-activator inhibitor type 1 (PAI-1) | SYSTEM | very-low-density lipoprotein receptor (VLDLr) | PROTEIN | LDL RECEPTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | PLASMINOGEN-ACTIVATOR INHIBITOR-1 | plasminogen-activator inhibitor type 1 (PAI-1) | serpin (serine protease inhibitor) | urokinase plasminogen activator (uPA) | COMPLEX-FORMATION | RAP COMPLEX | plasminogen-activator inhibitor type 2 (PAI-2) | DENSITY-LIPOPROTEIN-RECEPTOR | UROKINASE RECEPTOR | BINDING-SITE | LIGAND | Humans | Receptors, Cell Surface - metabolism | Receptors, LDL - metabolism | Plasminogen Activator Inhibitor 2 - physiology | Plasminogen Activator Inhibitor 1 - physiology | Breast Neoplasms - metabolism | Receptors, Urokinase Plasminogen Activator | Breast Neoplasms - chemistry | Plasminogen Activator Inhibitor 1 - chemistry | Plasminogen Activator Inhibitor 1 - metabolism | Urokinase-Type Plasminogen Activator - metabolism | Breast Neoplasms - pathology | Plasminogen Activator Inhibitor 2 - metabolism | Protein Structure, Secondary - physiology | Signal Transduction - physiology | Urokinase-Type Plasminogen Activator - chemistry | Tumor Cells, Cultured | Plasminogen Activator Inhibitor 2 - chemistry | Protein Binding - physiology | Protein Structure, Tertiary - physiology | uPA, urokinase plasminogen activator | LDLR, low-density lipoprotein receptor | serpin, serine protease inhibitor | uPAR, urokinase plasminogen activator receptor | VLDLr, very-low-density lipoprotein receptor | PAI, plasminogen-activator inhibitor | RAP, receptor-associated protein | RCL, reactive centre loop | ERK, extracellular-signal-regulated kinase | plasminogen-activator inhibitor type 1 (PAI-1) | LRP, low-density lipoprotein receptor-related protein | SPR, surface plasmon resonance | plasminogen-activator inhibitor type 2 (PAI-2)
Journal Article
Journal of Neurochemistry, ISSN 0022-3042, 07/2014, Volume 130, Issue 2, pp. 241 - 254
During early post‐natal development of the cerebellum, granule neurons (GN) execute a centripetal migration toward the internal granular layer, whereas basket... 
PACAP | tPA | granule neurons | basket and stellate cells | cerebellum | interneuron migration | NEURONAL MIGRATION | CYCLASE-ACTIVATING POLYPEPTIDE | TISSUE-PLASMINOGEN ACTIVATOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | NEUROSCIENCES | MICE LACKING | RAT CEREBELLUM | NEURITE OUTGROWTH | MESSENGER-RNA | CELL-MIGRATION | CENTRAL-NERVOUS-SYSTEM | Immunohistochemistry | Cerebellar Cortex - drug effects | Cerebellar Cortex - cytology | Rats, Wistar | Tissue Plasminogen Activator - metabolism | Cerebellar Cortex - growth & development | Cerebellum - drug effects | Interneurons - drug effects | Rats | Male | Cell Movement - drug effects | Animals | Tissue Plasminogen Activator - pharmacology | Plasminogen - pharmacology | Plasminogen Activator Inhibitor 1 - pharmacology | Cytoplasmic Granules - metabolism | Pituitary Adenylate Cyclase-Activating Polypeptide - pharmacology | Cerebellum - cytology | Cerebellum - growth & development | Female | Organ Culture Techniques | Brain | Tissue plasminogen activator | Proteases | Analysis | Neurochemistry | Pituitary gland | Rodents | Cerebellum | Cytoplasmic Granules | Interneurons | Pharmacology | Chemical Sciences | Life Sciences | Tissue Plasminogen Activator | Toxicology | Cerebellar Cortex | Plasminogen | Plasminogen Activator Inhibitor 1 | Pharmaceutical sciences | Cell Movement | Pituitary Adenylate Cyclase-Activating Polypeptide
Journal Article
European Journal of Neuroscience, ISSN 0953-816X, 03/2017, Volume 45, Issue 6, pp. 805 - 815
Glutamate phase shifts the circadian clock in the mammalian suprachiasmatic nucleus ( SCN ) by activating NMDA receptors. Tissue‐type plasminogen activator (... 
urokinase‐type plasminogen activator | circadian rhythms | suprachiasmatic nucleus | tissue‐type plasminogen activator | urokinase-type plasminogen activator | tissue-type plasminogen activator | NEURONAL MIGRATION | CELL-ADHESION MOLECULE | NEUROTROPHIC FACTOR | RECEPTOR | NEUROSCIENCES | IN-VITRO | EXTRACELLULAR-MATRIX | BIOLOGICAL CLOCK | BRAIN | GENE-FUNCTION | Brain-Derived Neurotrophic Factor - genetics | Suprachiasmatic Nucleus - drug effects | Tissue Plasminogen Activator - metabolism | Mice, Inbred C57BL | Plasminogen Inactivators - pharmacology | Male | Tissue Plasminogen Activator - genetics | Suprachiasmatic Nucleus - physiology | Animals | Urokinase-Type Plasminogen Activator - metabolism | Proteolysis | Circadian Clocks | Female | Suprachiasmatic Nucleus - metabolism | Brain-Derived Neurotrophic Factor - metabolism | Mice | Urokinase | Glutamate | Tissue plasminogen activator | Laws, regulations and rules | Suprachiasmatic nucleus | Glutamic acid | Brain | Night | Glutamic acid receptors (ionotropic) | Brain slice preparation | Nuclei | Plasmin | t-Plasminogen activator | Receptors | Casein | Rodents | Entrainment | Inhibition | Biological clocks | Circadian rhythms | Phase transformations | Phase shift | Polyamide-imides | N-Methyl-D-aspartic acid receptors | Circadian rhythm | Mammals | U-Plasminogen activator | Brain-derived neurotrophic factor | Inhibitors | Plasminogen activator inhibitors | TrkB receptors | Glutamatergic transmission | Gates
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 05/1999, Volume 99, Issue 18, pp. 2440 - 2444
Background-The role of plasminogen system components in focal cerebral ischemic infarction (FCI) was studied in mice deficient in plasminogen (Plg(-/-)), in... 
Cerebral infarction | Cerebral ischemia | Plasminogen activators | Plasminogen | INTRAVENOUS THROMBOLYSIS | TYPE-5 | CARDIAC & CARDIOVASCULAR SYSTEMS | DISORDERS | ACTIVATOR INHIBITOR-1 | DEFICIENT MICE | plasminogen | HIPPOCAMPUS | STROKE | ADENOVIRUS-MEDIATED TRANSFER | NEURONAL DEGENERATION | cerebral infarction | cerebral ischemia | PERIPHERAL VASCULAR DISEASE | GENERATION | plasminogen activators | HEMATOLOGY | Genetic Therapy | Urokinase-Type Plasminogen Activator - physiology | alpha-2-Antiplasmin - physiology | alpha-2-Antiplasmin - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Recombinant Fusion Proteins - physiology | Brain Ischemia - metabolism | Plasminogen - genetics | Male | Plasminogen - physiology | Tissue Plasminogen Activator - genetics | Plasminogen Activator Inhibitor 1 - physiology | Cerebral Infarction - metabolism | Transfection | Adenoviridae - genetics | Immunoglobulin G - pharmacology | Female | Plasminogen Activator Inhibitor 1 - deficiency | Plasminogen Activator Inhibitor 1 - genetics | alpha-2-Antiplasmin - genetics | Drug Evaluation, Preclinical | Cerebral Infarction - pathology | Recombinant Fusion Proteins - biosynthesis | Gene Targeting | Rabbits | alpha-2-Antiplasmin - deficiency | Immunoglobulin G - therapeutic use | Tissue Plasminogen Activator - physiology | Urokinase-Type Plasminogen Activator - genetics | Fibrinolysis | Genetic Vectors - genetics | Mice, Knockout | Animals | Brain Ischemia - pathology | Brain - pathology | Mice | alpha-2-Antiplasmin - immunology | Tissue Plasminogen Activator - deficiency | Urokinase-Type Plasminogen Activator - deficiency | Plasminogen - deficiency
Journal Article
American Journal of Physiology - Heart and Circulatory Physiology, ISSN 0363-6135, 10/2001, Volume 281, Issue 4, pp. 1784 - 1792
Plasminogen activator (PA) inhibitor-1 (PAI-1) has been recognized as a surrogate marker of endothelial dysfunction in diseases associated with impaired... 
Plasminogen activator inhibitor-1 | Metalloproteinase | RAT AORTA | CARDIAC & CARDIOVASCULAR SYSTEMS | PHYSIOLOGY | COLLAGEN | metalloproteinase | INVITRO | MICROVASCULAR ENDOTHELIAL-CELLS | MATRIX METALLOPROTEINASES | IN-VITRO | plasminogen activator inhibitor-1 | HUMAN MESANGIAL CELLS | PERIPHERAL VASCULAR DISEASE | GROWTH-FACTOR | EXPRESSION | UROKINASE | Mice, Knockout - genetics | Neovascularization, Physiologic - drug effects | Urokinase-Type Plasminogen Activator - physiology | Culture Techniques | Plasminogen - genetics | Fibrinolysin - physiology | Plasminogen - physiology | Tissue Plasminogen Activator - genetics | Plasminogen Activators - deficiency | Capillaries - physiology | Matrix Metalloproteinase 9 - metabolism | Plasminogen - pharmacology | Plasminogen Activator Inhibitor 1 - deficiency | Plasminogen Activator Inhibitor 1 - genetics | Plasminogen Activators - genetics | Matrix Metalloproteinase 2 - metabolism | Mice, Inbred C57BL | Tissue Plasminogen Activator - physiology | Urokinase-Type Plasminogen Activator - genetics | Neovascularization, Physiologic - physiology | Animals | Tissue Plasminogen Activator - pharmacology | Plasminogen Activator Inhibitor 1 - pharmacology | Mice | Plasminogen Activators - pharmacology | Urokinase-Type Plasminogen Activator - pharmacology | Tissue Plasminogen Activator - deficiency | Urokinase-Type Plasminogen Activator - deficiency | Plasminogen - deficiency
Journal Article
Cellular and Molecular Life Sciences, ISSN 1420-682X, 10/1999, Volume 56, Issue 1, pp. 104 - 132
The regulation of plasminogen activation involves genes for two plasminogen activators (tissue type and urokinase type), two specific inhibitors (type 1 and... 
cell motility | fibrinolysis | Cell invasion | metastasis | signal transduction | transcriptional regulation | plasminogen activator | plasminogen activator inhibitor | uPA receptor | mRNA stability | Cell motility | Signal transduction | Plasminogen activator | Metastasis | Plasminogen activator inhibitor | Transcriptional regulation | Fibrinolysis | 3' UNTRANSLATED REGION | PROTEIN-KINASE-C | RECEPTOR-BOUND UROKINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | INHIBITOR TYPE-2 GENE | HUMAN-ENDOTHELIAL-CELLS | CAMP-RESPONSIVE ELEMENT | MESSENGER-RNA STABILITY | CELL BIOLOGY | TUMOR-NECROSIS-FACTOR | GROWTH-FACTOR-BETA | PHORBOL-MYRISTATE-ACETATE | cell invasion | Plasminogen Activator Inhibitor 2 - genetics | Signal Transduction | Humans | Gene Expression Regulation | Receptors, Cell Surface - metabolism | Plasminogen - metabolism | Urokinase-Type Plasminogen Activator - genetics | RNA, Messenger - metabolism | Receptors, Urokinase Plasminogen Activator | Plasminogen Activators - physiology | Animals | Plasminogen Activator Inhibitor 1 - metabolism | Urokinase-Type Plasminogen Activator - metabolism | Plasminogen Activator Inhibitor 2 - metabolism | Plasminogen Activator Inhibitor 1 - genetics | Plasminogen Activators - genetics | Receptors, Cell Surface - genetics | Thrombolytic drugs | Proteins | Cellular biology | Gene expression | Cell adhesion & migration
Journal Article
Journal Article
Strahlentherapie und Onkologie, ISSN 0179-7158, 6/2018, Volume 194, Issue 6, pp. 539 - 551
The urokinase plasminogen activator system (uPA, uPAR, PAI‑1) is upregulated in cancer and high plasma levels are associated with poor prognosis. Their... 
Prognose | Biomarker | Prognosis | Oncology | Urokinase plasminogen activator (uPA) | Urokinase plasminogen activator receptor (uPAR) | Radiotherapy | Urokinase-Plasminogen-Aktivator (uPA) | Strahlentherapie | Medicine & Public Health | Non-small-cell lung cancer (NSCLC) | Urokinase-Plasminogen-Aktivator-Rezeptor (uPAR) | Nicht-kleinzelliges Bronchialkarzinom (NSCLC) | Plasminogen-activator inhibitor 1 (PAI-1) | Plasminogen-Aktivator-Inhibitor 1 (PAI-1) | Urokinase plasminogen activator receptor ( uPAR) | UPA | TISSUE | RECEPTOR | CLINICAL-RELEVANCE | BREAST-CANCER | RECTAL-CANCER | MESSENGER-RNA | ONCOLOGY | PLASMA-LEVELS | INHIBITOR PAI-1 | Plasminogen-activator inhibitor 1 (PAI-1) | EXPRESSION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Carcinoma, Non-Small-Cell Lung - pathology | Osteopontin - blood | Carcinoma, Non-Small-Cell Lung - radiotherapy | Prospective Studies | Enzyme-Linked Immunosorbent Assay | Humans | Translational Medical Research | Lung Neoplasms - radiotherapy | Lung Neoplasms - pathology | Palliative Care | Receptors, Urokinase Plasminogen Activator - blood | Combined Modality Therapy | Statistics as Topic | Chemoradiotherapy | Plasminogen Activator Inhibitor 1 - blood | Tumor Burden - physiology | Biomarkers, Tumor - blood | Carcinoma, Non-Small-Cell Lung - blood | Lung Neoplasms - blood | Neoplasm Staging | Urokinase-Type Plasminogen Activator - blood | Plasma | Lung cancer | Risk | Radiation therapy | Multivariate analysis | Survival | Patients | Urokinase | Medical prognosis | Biocompatibility | Hypoxia | Death | Pretreatment | Cancer
Journal Article